Winston Yap
Family Medicine · Bedford, KYNPI 1548288533
Payments from drug & device makers
Across 647 payments — averaging $39.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- AbbVie$2K
- GSK$2K
- Novo Nordisk$2K
- Medtronic$2K
- Amgen$2K
- plus $11K from 46 others
What the payments were for
- Travel & lodging$1,0974%
- Food & beverage$24,15696%
- Education$400%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,293 in reported general payments places this provider in the 95th percentile of 1,559 family medicine providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $106,795 |
| OzempicSemaglutide | 61 | $77,511 |
| FarxigaDapagliflozin Propanediol | 83 | $67,894 |
| JardianceEmpagliflozin | 54 | $60,005 |
| EntrestoSacubitril/Valsartan | 36 | $45,552 |
| EliquisApixaban | 44 | $33,856 |
| TrulicityDulaglutide | 21 | $31,822 |
| Invega SustennaPaliperidone Palmitate | 11 | $24,657 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $23,216 |
| Nurtec OdtRimegepant Sulfate | 12 | $22,988 |
| LinzessLinaclotide | 28 | $22,714 |
| KerendiaFinerenone | 25 | $21,009 |
| XareltoRivaroxaban | 20 | $18,210 |
| VascepaIcosapent Ethyl | 22 | $15,673 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $12,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $2,231 | $112,691123 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $3,259 | $91,109110 claims |
| Novo NordiskOzempic | $2,203 | $77,51161 claims |
| Boehringer IngelheimJardiance | $578 | $60,00554 claims |
| PfizerEliquis, Nurtec Odt | $527 | $56,84456 claims |
| NovartisEntresto | $928 | $45,55236 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $880 | $42,86731 claims |
| Lilly USA, LLCTrulicity | $303 | $31,82221 claims |
| AbbVieLinzess | $2,278 | $22,71428 claims |
| BayerKerendia | $329 | $21,00925 claims |
| Esperion Therapeutics, Inc.Nexlizet | $559 | $12,50812 claims |
| MerckVerquvo | $198 | $11,12513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Bedford
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.